[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100579423":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":32,"responsibleParty":214,"collaborators":29,"id":216,"slug":29,"hasResults":217,"nctId":218,"briefTitle":219,"officialTitle":220,"acronym":29,"eligibilityCriteria":221,"healthyVolunteers":217,"sex":222,"minAge":223,"maxAge":224,"enrollmentInfo":225,"targetDuration":29,"studyType":228,"phases":229,"briefSummary":231,"conditions":232,"keywords":236,"overallStatus":35,"whyStopped":29,"lastUpdateSubmitDate":245,"lastUpdatePostDateStruct":246,"startDateStruct":249,"completionDateStruct":251,"leadSponsor":253,"locationsCount":254},{"fullName":5,"class":6},"Novartis","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Ruxolitinib","EXPERIMENTAL","Chinese participants (adult and pediatric) who will receive ruxolitinib daily.",[13],"Drug: Ruxolitinib",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","Ruxolitinib is taken orally daily at 10 mg BID, given as two 5 mg tablets.",[9],[20],"INC424",[22],{"name":23,"affiliation":23,"role":24},"Novartis Pharmaceuticals","STUDY_DIRECTOR",[26,31],{"name":23,"role":27,"phone":28,"phoneExt":29,"email":30},"CONTACT","+41613241111",null,"novartis.email@novartis.com",{"name":23,"role":27,"phone":29,"phoneExt":29,"email":29},[33,46,55,60,69,78,87,96,105,114,122,131,135,144,153,161,169,177,182,190,198,206],{"facility":34,"status":35,"city":36,"state":37,"zip":38,"country":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":29},"Novartis Investigative Site","RECRUITING","Hefei","Anhui","230001","China",{"type":41,"coordinates":42},"Point",[43,44],117.28083,31.86389,{"lat":44,"lon":43},{"facility":34,"status":35,"city":47,"state":48,"zip":49,"country":39,"cosmosGeoPoint":50,"geoPoint":54,"contacts":29},"Guangzhou","Guangdong","510000",{"type":41,"coordinates":51},[52,53],113.25,23.11667,{"lat":53,"lon":52},{"facility":34,"status":35,"city":47,"state":48,"zip":56,"country":39,"cosmosGeoPoint":57,"geoPoint":59,"contacts":29},"510515",{"type":41,"coordinates":58},[52,53],{"lat":53,"lon":52},{"facility":34,"status":35,"city":61,"state":62,"zip":63,"country":39,"cosmosGeoPoint":64,"geoPoint":68,"contacts":29},"Nanning","Guangxi","530021",{"type":41,"coordinates":65},[66,67],108.31667,22.81667,{"lat":67,"lon":66},{"facility":34,"status":35,"city":70,"state":71,"zip":72,"country":39,"cosmosGeoPoint":73,"geoPoint":77,"contacts":29},"Guiyang","Guizhou","550004",{"type":41,"coordinates":74},[75,76],106.71667,26.58333,{"lat":76,"lon":75},{"facility":34,"status":35,"city":79,"state":80,"zip":81,"country":39,"cosmosGeoPoint":82,"geoPoint":86,"contacts":29},"Shijiazhuang","Hebei","050000",{"type":41,"coordinates":83},[84,85],114.47861,38.04139,{"lat":85,"lon":84},{"facility":34,"status":35,"city":88,"state":89,"zip":90,"country":39,"cosmosGeoPoint":91,"geoPoint":95,"contacts":29},"Zhengzhou","Henan","450003",{"type":41,"coordinates":92},[93,94],113.64861,34.75778,{"lat":94,"lon":93},{"facility":34,"status":35,"city":97,"state":98,"zip":99,"country":39,"cosmosGeoPoint":100,"geoPoint":104,"contacts":29},"Wuhan","Hubei","430030",{"type":41,"coordinates":101},[102,103],114.26667,30.58333,{"lat":103,"lon":102},{"facility":34,"status":35,"city":106,"state":107,"zip":108,"country":39,"cosmosGeoPoint":109,"geoPoint":113,"contacts":29},"Nanjing","Jiangsu","210029",{"type":41,"coordinates":110},[111,112],118.77778,32.06167,{"lat":112,"lon":111},{"facility":34,"status":35,"city":115,"state":107,"zip":116,"country":39,"cosmosGeoPoint":117,"geoPoint":121,"contacts":29},"Xuzhou","221003",{"type":41,"coordinates":118},[119,120],117.28386,34.20442,{"lat":120,"lon":119},{"facility":34,"status":35,"city":123,"state":124,"zip":125,"country":39,"cosmosGeoPoint":126,"geoPoint":130,"contacts":29},"Nanchang","Jiangxi","330006",{"type":41,"coordinates":127},[128,129],115.85306,28.68396,{"lat":129,"lon":128},{"facility":34,"status":35,"city":132,"state":133,"zip":134,"country":39,"cosmosGeoPoint":29,"geoPoint":29,"contacts":29},"Xian","Shanxi","710061",{"facility":34,"status":35,"city":136,"state":137,"zip":138,"country":39,"cosmosGeoPoint":139,"geoPoint":143,"contacts":29},"Chengdu","Sichuan","610041",{"type":41,"coordinates":140},[141,142],104.06667,30.66667,{"lat":142,"lon":141},{"facility":34,"status":35,"city":145,"state":146,"zip":147,"country":39,"cosmosGeoPoint":148,"geoPoint":152,"contacts":29},"Hangzhou","Zhejiang","310003",{"type":41,"coordinates":149},[150,151],120.16142,30.29365,{"lat":151,"lon":150},{"facility":34,"status":35,"city":154,"state":146,"zip":155,"country":39,"cosmosGeoPoint":156,"geoPoint":160,"contacts":29},"Ningbo","315016",{"type":41,"coordinates":157},[158,159],121.54945,29.87819,{"lat":159,"lon":158},{"facility":34,"status":35,"city":162,"state":146,"zip":163,"country":39,"cosmosGeoPoint":164,"geoPoint":168,"contacts":29},"Wenzhou","325000",{"type":41,"coordinates":165},[166,167],120.66682,27.99942,{"lat":167,"lon":166},{"facility":34,"status":35,"city":170,"state":29,"zip":171,"country":39,"cosmosGeoPoint":172,"geoPoint":176,"contacts":29},"Beijing","100034",{"type":41,"coordinates":173},[174,175],116.39723,39.9075,{"lat":175,"lon":174},{"facility":34,"status":35,"city":170,"state":29,"zip":178,"country":39,"cosmosGeoPoint":179,"geoPoint":181,"contacts":29},"100070",{"type":41,"coordinates":180},[174,175],{"lat":175,"lon":174},{"facility":34,"status":35,"city":183,"state":29,"zip":184,"country":39,"cosmosGeoPoint":185,"geoPoint":189,"contacts":29},"Changsha","410000",{"type":41,"coordinates":186},[187,188],112.97087,28.19874,{"lat":188,"lon":187},{"facility":34,"status":35,"city":191,"state":29,"zip":192,"country":39,"cosmosGeoPoint":193,"geoPoint":197,"contacts":29},"Chongqing","400016",{"type":41,"coordinates":194},[195,196],106.55771,29.56026,{"lat":196,"lon":195},{"facility":34,"status":35,"city":199,"state":29,"zip":200,"country":39,"cosmosGeoPoint":201,"geoPoint":205,"contacts":29},"Shanghai","200025",{"type":41,"coordinates":202},[203,204],121.45806,31.22222,{"lat":204,"lon":203},{"facility":34,"status":35,"city":207,"state":29,"zip":208,"country":39,"cosmosGeoPoint":209,"geoPoint":213,"contacts":29},"Wujiang Nongchang","065201",{"type":41,"coordinates":210},[211,212],79.81606,33.6106,{"lat":212,"lon":211},{"type":215,"investigatorFullName":29,"investigatorTitle":29,"investigatorAffiliation":29,"oldNameTitle":29,"oldOrganization":29},"SPONSOR","100579423",false,"NCT06824103","Study of Efficacy and Safety of Ruxolitinib in Chinese Participants With Corticosteroid-refractory Chronic Graft vs. Host Disease","A Single-arm Multi-center Study of Ruxolitinib in Chinese Participants With Corticosteroid-refractory Chronic Graft Versus Host Disease After Allogeneic Stem Cell Transplantation","Inclusion Criteria:\n\n* Signed informed consent must be obtained prior to participation in the study.\n* Male or female Chinese participants aged 12 or older at the time of informed consent\n* Able to swallow tablets.- Have undergone alloSCT from any donor source (matched unrelated donor, sibling, haplo-identical) using bone marrow, peripheral blood stem cells, or cord blood. Recipients of non-myeloablative, myeloablative, and reduced intensity conditioning are eligible.\n* Evident myeloid and platelet engraftment:\n\n  * Absolute neutrophil count (ANC) \\>1,000\u002Fmm3 AND\n  * Platelet count ≥25,000\u002Fmm3\n\nNote: Use of growth factor supplementation and transfusion support is allowed during the trial, however, transfusion to reach a minimum platelet count for inclusion is not allowed during screening and at baseline.\n\n* Participants with clinically diagnosed cGvHD staging of moderate to severe according to NIH Consensus Criteria (Jagasia et al 2015) prior to Cycle 1 Day 1.\n\n  * Moderate cGvHD: at least one organ (not lung) with a score of 2, 3 or more organs involved with a score of 1 in each organ, or lung score of 1.\n  * Severe cGvHD: at least 1 organ with a score of 3, or lung score of 2 or 3.\n* Participants currently receiving systemic corticosteroids for the treatment of cGvHD for a duration of \\\u003C 12 months prior to Cycle 1 Day 1, and have a confirmed diagnosis of corticosteroid refractory cGvHD defined per 2014 NIH consensus criteria (Martin et al 2015) irrespective of the concomitant use of a calcineurin inhibitor, as follows:\n\n  * A lack of response or disease progression after administration of minimum prednisone 1 mg\u002Fkg\u002Fday for at least 1 week (or equivalent) OR\n  * Disease persistence without improvement despite continued treatment with prednisone at \\>0.5 mg\u002Fkg\u002Fday or 1 mg\u002Fkg\u002Fevery other day for at least 4 weeks (or equivalent) OR\n  * Increase to prednisone dose to \\>0.25 mg\u002Fkg\u002Fday after two unsuccessful attempts to taper the dose (or equivalent)\n* Participants has Eastern Cooperative Oncology Group (ECOG) performance status of 0-2\n\nExclusion Criteria:\n\nFor a full list of exclusion criteria, refer to Section 5.2. Key exclusion criteria include\n\n* Participants who have received two or more systemic treatments for cGvHD in addition to corticosteroids ± CNI for cGvHD.\n* Participants who have received ROCK2 inhibitors for cGvHD.\n* Participants that transition from active aGvHD to cGvHD without tapering off corticosteroids ± CNI and any systemic treatment\n\nNote: Participants receiving up to 30 mg by mouth once a day of hydrocortisone (i.e., physiologic replacement dose) of corticosteroids are allowed.\n\n* Participants who were treated with prior JAK inhibitors for aGvHD; except when the participant achieved complete or partial response and has been off JAK inhibitor treatment for at least 8 weeks prior to Cycle 1 Day 1.\n* Failed prior alloSCT within the past 6 months from Cycle 1 Day 1.\n* Participants with relapsed primary malignancy, or who have been treated for relapse after the alloSCT was performed.\n* SR-cGvHD occurring after a non-scheduled donor lymphocyte infusion (DLI) administered for pre-emptive treatment of malignancy recurrence. Participants who have received a scheduled DLI as part of their transplant procedure and not for management of malignancy relapse are eligible.\n\nOther protocol-defined inclusion\u002Fexclusion may apply.","ALL","12 Years","100 Years",{"count":226,"type":227},50,"ESTIMATED","INTERVENTIONAL",[230],"PHASE4","The purpose of the study is to assess the efficacy and safety of ruxolitinib in Chinese adult and pediatric participants aged 12 years or older with corticosteroid-refractory chronic graft vs. host disease (SR-cGvHD).",[233,234,235],"Graft vs. Host Disease","Chronic Graft vs. Host Disease","Corticosteroid-refractory Chronic Graft vs. Host Disease",[237,238,239,240,20,241,242,243,244],"cGvHD","GvHD","SR-cGvHD","ruxolitinib","Chinese adult","Pediatric","Corticosteroid","refractory","2026-06-04",{"date":247,"type":248},"2026-06-08","ACTUAL",{"date":250,"type":248},"2025-09-09",{"date":252,"type":227},"2031-05-23",{"name":23,"class":6},22]